AOA Dx is developing GlycoLocate™, a multi-omics platform that utilizes tumor marker gangliosides for early-stage cancer detection, specifically through the AKRIVIS GD™ liquid biopsy test for ovarian cancer. This technology offers high sensitivity and specificity, addressing the critical need for effective early diagnosis in women's health.

Basepaws offers at-home genetic testing for cats and dogs using DNA analysis to provide detailed insights into breed composition, health markers, and dental health risks. This service enables pet owners to proactively manage their pets' health by identifying genetic predispositions and informing care decisions.

CatenaBio has developed the CysTyr™ platform, which utilizes the Catenase™ enzyme to form proprietary C-Y Bonds™ between proteins using native amino acids, enabling the rapid and selective attachment of multiple therapeutic modalities. This technology addresses the limitations of current protein conjugation methods, facilitating the creation of novel therapeutics for autoimmune disorders, oncology, and vaccine development.

Constructive.Bio utilizes a dual-technology platform that combines de novo genome synthesis and engineered translation to create programmable biomolecules with high fidelity. This approach addresses the limitations of traditional biomanufacturing by enabling the production of customized bioproducts, including phage-resistant strains and next-generation therapeutics.

Deep Longevity employs artificial intelligence to analyze biomarkers of aging, enabling accurate evaluations of biological age. This technology provides essential insights into the aging process, facilitating personalized health interventions and advancements in longevity research.

Freedom Biosciences is a biotechnology platform developing next-generation neuropsychiatric therapeutics based on ketamine pharmacology. The company focuses on creating novel antidepressants with improved efficacy and safety profiles for debilitating mental health disorders. Their pipeline includes clinical and preclinical programs targeting treatment-resistant depression and comorbid substance use disorders.

Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.

Haut.AI provides an AI-powered skin analysis platform that evaluates over 150 facial biomarkers using advanced algorithms to deliver personalized skincare product recommendations. This technology enables beauty brands to enhance customer engagement and increase average order values by offering tailored solutions based on individual skin health metrics.

Insilico Medicine utilizes a generative AI platform to streamline drug discovery and development for cancer and age-related diseases, significantly reducing the time and cost associated with bringing new medications to market. The platform integrates multi-omics data analysis and machine learning to identify novel drug targets and predict clinical trial outcomes, enhancing the efficiency of pharmaceutical research.

Interface Bio develops next-generation, multi-targeted immunotherapies by integrating human biology and Artificial Intelligence. The company leverages a platform that mines natural product chemical scaffolds from commensal microbes for therapeutic development. This approach aims to generate safe and effective drug candidates for complex diseases like cancer and autoimmune disorders at an accelerated rate.

Provides a blockchain-based platform that enables secure, compliant sharing and monetization of personal health data between patients, healthcare providers, and life science companies. This system streamlines post-market research, patient engagement, and real-world evidence generation, improving cohort identification, treatment adherence, and market access for novel therapies.

MediSix Therapeutics develops proprietary T-cell therapies, utilizing their unique Protein Expression BLocker (PEBL) technology to enhance T-cell function for patients with T-cell malignancies. The company addresses the limitations of existing CAR T-cell therapies, aiming to improve treatment outcomes for complex and rare cancers and autoimmune diseases.

Melio is developing a rapid blood testing platform that utilizes proprietary assays and microfluidics to identify pathogens within hours, significantly reducing the time required for diagnosis compared to traditional blood cultures. This technology addresses the critical need for timely and accurate detection of bloodborne infections, particularly for vulnerable populations such as newborns in the NICU.

The startup has developed an automated microtumor-based profiling technology for in vitro cancer diagnosis, enabling clinical institutions to evaluate the efficacy of various cancer drugs and combinations directly on patient-derived micro-tumors. This approach enhances treatment selection for physicians, ultimately improving patient outcomes in cancer management.

Red Queen Bio provides an AI‑driven platform that maps potential AI‑generated biothreats and automatically designs therapeutic countermeasures such as antibodies, antivirals, and vaccine antigens. The system integrates large‑scale protein language models, reinforcement‑learning optimization, and fully automated wet‑lab workflows with on‑demand biologics manufacturing, delivering ready‑to‑produce sequences via secure APIs and a web dashboard for biodefense agencies and biotech labs.

Rubedo Life Sciences is a clinical-stage biotech company focused on developing therapeutics that target the pathologic cells driving aging. The company utilizes its Alembic discovery platform to identify novel drug candidates aimed at promoting biological youthfulness. Their pipeline includes GPX4 modulators designed to address chronic diseases associated with the aging process.

This company provides at-home blood testing kits that allow users to painlessly collect samples without visiting a lab. Members receive comprehensive biomarker analysis across categories like cardiovascular, hormonal, and metabolic health. The service delivers results with personalized action plans and supplement recommendations to optimize user healthspan.

Nexus App is a ride-sharing platform that utilizes electric vehicles to provide sustainable transportation while significantly reducing carbon emissions. The service addresses the need for eco-friendly commuting options in urban areas, contributing to lower air pollution and a smaller carbon footprint.

Turn is a company listed at turn.bio, but no publicly available information is provided about its product, service, or target market.

Unnatural Products utilizes an AI-enhanced discovery platform to engineer synthetic macrocycles that mimic natural macrocycles, enabling targeted therapies for complex drug targets that are typically undruggable by small molecules or biologics. This approach addresses the limitations of existing drug modalities by providing a new class of therapeutics with improved cell permeability and oral bioavailability.

Valink Therapeutics develops next-generation bispecific antibody-drug conjugates (ADCs) designed for enhanced tumor targeting and reduced off-target toxicity. Their proprietary V-Gate approach enables continuous, tunable drug activation based on multiple molecular targets present on cancer cells. This technology aims to create more effective oncology therapeutics capable of treating diseases resistant to current options.